[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperlipidemia-eg-hypercholesterolemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperlipidemia-eg-hypercholesterolemia":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":37,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100639368","phase-2-use-of-bile-acid-binding-resins-to-decrease-pfas-levels-via-colesevalem-in-veterans-study-100639368",false,"NCT07592858","Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study","Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study","PAVERS","Inclusion:\n\n* Male or female Veterans aged 25- 65 who have serum PFAS \\>20 ng\u002Fml exceeding National Academy of Science guidance.\n* Written informed consent will be obtained.\n* Outpatient.\n* Agreeable to participate in sharable data and biorepository.\n\nExclusion:\n\n* Under the age of 25 years\n* Unable or unwilling to sign the informed consent statement and HIPAA Authorization form\n* Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period.\n* Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction\n* Be receiving any investigational drug other than Colesevelam or participating in any other investigational study.\n* Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator.\n* Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results.\n* Those with significant cardiovascular disease including treatment with inotropes.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.",true,"ALL","25 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix \\> 20 ng\u002Fml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.",[29,30,31,32,33,34,35,36],"PFAS","Environmental Exposures","Occupational Exposure to Chemicals","Military Exposure","Burn Pit Exposure","Forever Chemicals","Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia","Hyperlipidemia (E.G., Hypercholesterolemia)",[29,38,39,40],"Military exposure","Forever chemicals","Colesevelam","NOT_YET_RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-18","ACTUAL",{"date":47,"type":23},"2026-07-01",{"date":49,"type":23},"2029-09-29",{"name":51,"class":52},"University of Rhode Island","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":66,"conditions":67,"keywords":75,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100580200","advancing-care-coordination-between-cancer-and-primary-care-teams-for-complex-cancer-survivors-100580200","NCT06834204","Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors","ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Cancer Survivors in Primary Care.","ACCESS-PC","Inclusion Criteria:\n\n* diagnosed with any of the following cancers \\[Stage I-III\\]: breast, prostate, urinary bladder, and endometrial in the past 6 months;\n* being treated for cancer with curative intent;\n* had initial patient visit at the cancer center in the last 3 months;\n* are being treated for cancer with curative intent at the Rutgers Cancer Institute of New Jersey\n* have ≥1 CVD risk factor (hypertension, hyperlipidemia or type II diabetes) prior to cancer diagnosis that requires medication management;\n* currently receiving care from a primary care provider;\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* had myocardial infarction or stroke within the previous 1 year;\n* have heart failure with an ejection fraction \\\u003C30%; (3) have stage IV-V chronic kidney disease (eGFR \\\u003C30);\n* or do not speak English or Spanish. Patients whose cancer progresses to metastatic disease during the course of the 18-month trial will be allowed to continue to participate unless they voluntarily withdraw","18 Years",{"count":63,"type":23},266,[65],"NA","The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on \"complex\" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and\u002For hyperlipidemia) requiring medication management. This study also aims to learn about the ease of implementing the health system intervention from the perspectives of cancer teams, primary care teams, and complex cancer patients.\n\nThe main questions the study aims to answer are:\n\n* Do patients enrolled in the PC2 arm remain connected to their primary care teams during active cancer treatment for chronic disease management compared to patients in usual care?\n* Do patients enrolled in the PC2 arm have better management of their chronic conditions during active cancer treatment compared to patients in usual care?\n* How do the care team and patients experience this change in care delivery related to their work and care experiences?\n\nThis study will compare complex cancer survivors who receive care according to the PC2 intervention to usual care to see if PC2 works to improve cardiovascular risk management.\n\nParticipants will:\n\n* receive educational materials about the study upon enrollment\n* complete on-line or written surveys at 4 times\n* Visit the clinic for check ups and test related to the study 4 times",[68,69,70,71,72,73,36,74],"Cancer","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Bladder Cancer","Prostate Cancer (Adenocarcinoma)","Endometrial Cancer","Hypertension","Diabetes Mellitus",[76,77,78,79,80,81,82,83],"primary care","cancer","cardiovascular","shared care","care coordination","implementation","cancer multi-team system","complex cancer survivor","2026-03-20",{"date":86,"type":45},"2026-03-23",{"date":88,"type":23},"2026-04-15",{"date":90,"type":23},"2029-04-30",{"name":92,"class":52},"Rutgers, The State University of New Jersey",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":93},"100576756","phase-4-efficacy-and-safety-of-atorvastatin-and-ezetimibe-1010mg-fixed-dose-combination-versus-atorvastatin-20mg-monotherapy-in-bangladeshi-population-100576756","NCT06789432","Efficacy and Safety of Atorvastatin and Ezetimibe (10\u002F10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","Inclusion Criteria:\n\n* Men and women aged \\>18 years.\n* Patients with a confirmed diagnosis of elevated LDL-C levels necessitating medical management.\n* Patients in the low to moderate cardiovascular disease (CVD) risk category according to ESC guidelines (2019)\n\n  * Low-risk: Increased LDL-C level without any co-morbidities\n  * Moderate-risk: Young patients (T1DM \\\u003C35 years; T2DM \\\u003C50 years) with DM duration \\\u003C10 years, without other risk factors.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any study drugs.\n* Clinically significant hepatic impairment (ALT, AST level \\> 2xULN) and\u002For renal impairment (Serum creatinine level ≥2xULN).\n* Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, cancer, psychiatric instability, HIV + status, intestinal malabsorption.\n* Pregnant or lactating females.\n* The presence of a condition that, in the opinion of the investigator, would place the subject at increased risk from study participation.",{"count":101,"type":23},500,[103],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population.\n\nResearchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia.\n\nParticipants will:\n\n* Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months\n* Follow-up visits at 6 weeks and 12 weeks for checkups and tests",[36],[107,108,109],"increased LDL-C level","Hyperlipidemia","Atorvastatin (10 mg) and Ezetimibe (10 mg)","RECRUITING","2025-07-25",{"date":113,"type":45},"2025-07-29",{"date":115,"type":45},"2025-02-01",{"date":117,"type":23},"2025-12",{"name":119,"class":120},"Dr. Md. Alimur Reza","INDUSTRY"]